Published in Am J Case Rep on October 24, 2016
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol (2004) 9.05
Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A (1976) 4.89
The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact (1974) 3.91
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol (1997) 2.28
Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg (1997) 2.23
Optic gliomas in children with neurofibromatosis type 1. J Pediatr (1989) 1.76
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol (1997) 1.47
Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses (1995) 1.36
Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol (1993) 1.32
Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol (1999) 1.29
Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet (1999) 1.29
Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A (2003) 1.28
Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol (2007) 1.20
Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents. Biochem J (2010) 1.17
Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology (2004) 1.13
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol (2002) 1.07
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol (2013) 1.07
Nutritional factors in the etiology of brain tumors: potential role of nitrosamines, fat, and cholesterol. Am J Epidemiol (1997) 1.02
High levels of ascorbic acid, not glutathione, in the CNS of anoxia-tolerant reptiles contrasted with levels in anoxia-intolerant species. J Neurochem (1995) 0.99
Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med (2008) 0.92
Optic radiation involvement in optic pathway gliomas in neurofibromatosis. Am J Ophthalmol (2004) 0.92
Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med (2013) 0.90
Dietary prevention of malignant glioma aggressiveness, implications in oxidant stress and apoptosis. Int J Cancer (2008) 0.88
Inverse association of antioxidant and phytoestrogen nutrient intake with adult glioma in the San Francisco Bay Area: a case-control study. BMC Cancer (2006) 0.86
Vitamin D receptor expression in human brain tumors. J Neurosurg Sci (1992) 0.81
Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblastoma multiforme cells: modulation of insulin-like growth factor-I receptor (IGF-IR) expression. J Neurooncol (2001) 0.80
Vitamin D metabolites activate the sphingomyelin pathway and induce death of glioblastoma cells. Acta Neurochir (Wien) (1998) 0.80
Targeting the NF-E2-related factor 2 pathway: a novel strategy for glioblastoma (review). Oncol Rep (2014) 0.80
Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents. Nutr Cancer (2011) 0.79
Effects of vitamin D and retinoic acid on human glioblastoma cell lines. Acta Neurochir (Wien) (1995) 0.77
Ascorbic acid upregulates myelin gene expression in C6 glioma cells. Metab Brain Dis (1992) 0.77
Modulation of Cytokines in Cancer Patients by Intravenous Ascorbate Therapy. Med Sci Monit (2016) 0.77